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Abstract: Direct oral anticoagulants (DOAC) have shown an upward prescribing trend in recent
years due to favorable pharmacokinetics and pharmacodynamics without requirement for routine
coagulation monitoring. However, recent studies have documented inter-individual variability in
plasma drug levels of DOACs. Pharmacogenomics of DOACs is a relatively new area of research.
There is a need to understand the role of pharmacogenomics in the interpatient variability of the
four most commonly prescribed DOACs, namely dabigatran, rivaroxaban, apixaban, and edoxaban.
We performed an extensive search of recently published research articles including clinical trials
and in-vitro studies in PubMed, particularly those focusing on genetic loci, single nucleotide
polymorphisms (SNPs), and DNA polymorphisms, and their effect on inter-individual variation of
DOACs. Additionally, we also focused on commonly associated drug-drug interactions of DOACs.
CES1 and ABCB1 SNPs are the most common documented genetic variants that contribute to alteration
in peak and trough levels of dabigatran with demonstrated clinical impact. ABCB1 SNPs are
implicated in alteration of plasma drug levels of rivaroxaban and apixaban. Studies conducted
with factor Xa, ABCB1, SLCOB1, CYP2C9, and VKORC1 genetic variants did not reveal any
significant association with plasma drug levels of edoxaban. Pharmacokinetic drug-drug interactions
of dabigatran are mainly mediated by p-glycoprotein. Strong inhibitors and inducers of CYP3A4
and p-glycoprotein should be avoided in patients treated with rivaroxaban, apixaban, and edoxaban.
We conclude that some of the inter-individual variability of DOACs can be attributed to alteration
of genetic variants of gene loci and drug-drug interactions. Future research should be focused on
exploring new genetic variants, their effect, and molecular mechanisms that contribute to alteration
of plasma levels of DOACs.
Keywords: direct oral anticoagulant; dabigatran; rivaroxaban; apixaban; edoxaban; pharmacogenomics;
genetic variants; SNPs; gene-drug interactions; genome guided therapy
1. Introduction
Warfarin has been the main oral anticoagulant in clinical use since its discovery in 1954 by
Wisconsin Alumini Research Foundation [1]. The underlying mechanism through which it exerts its
anticoagulant effect are numerous, including inhibition of vitamin K epoxide reductase, attenuating
vitamin K-dependent γ-carboxylation of coagulation factors II, VII, IX and, X.; and inhibition of protein
C and S [2]. Despite the extensive clinical use of warfarin, it has many limitations such as slow onset of
action, narrow therapeutic window, inadequate anticoagulation, increased risk of bleeding, frequent
drug and food interactions, and need for frequent laboratory monitoring [3].
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To offset these limitations, there was a need to develop alternative therapeutic options. New direct
oral anticoagulants (DOAC) that are now used in clinical practice include dabigatran, rivaroxaban,
apixaban, and edoxaban [4–7]. They are unique in acting on only a single coagulation factor (either
thrombin or factor Xa) and target clot formation and fibrin deposition [3]. The current usage of DOACs
has been increasing at a rapid rate over recent years [8]. Specifically, rivaroxaban usage increased from
0.13% to 13.87% from 2011 to 2014, whereas dabigatran usage increased from 1.3% to 7.6% from 2011
to 2014 [9].
The advantages of DOACs include high bioavailability, rapid onset of action, wide therapeutic
window, no food interactions, few drug interactions, predictable pharmacokinetic and pharmacodynamic
profiles, and no coagulation monitoring [2,3,10]. Due to the wide therapeutic range of DOACs, they are
offered in fixed dosage schedules, which can be more convenient for patients [11].
The disadvantages of DOACs include higher cost, caution in liver and kidney impairment,
a contraindication during pregnancy, and lack of clinical efficacy in thromboprophylaxis in setting
of mechanical valves [2,10]. Currently approved uses of DOACs include prevention of stroke and
thromboembolism in non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and
pulmonary embolism (PE), and prevention of venous thromboembolism in knee/hip surgery [12].
Dabigatran may be preferred in patients with higher risk of stroke and thromboembolism and low risk
of bleeding [13,14]. Apixaban may be preferred in elderly patients with high risk of thromboembolism,
high bleeding risk, and moderate renal dysfunction [13,14]. Edoxaban may have advantages in patients
with low thromboembolism and high bleeding risk [13]. Rivaroxaban once daily dosing regimen is the
most convenient for indication of atrial fibrillation and may be preferred in patients with dyspepsia
and medication compliance concerns [13,14].
Recently, specific antidotes have become available to treat major and life threatening bleeding
related to DOACs, namely idarucizumab (mono-clonal antibody) for dabigatran and andexanet
alpha (recombinant modified factor Xa) for factor Xa inhibitors [15,16]. Variation in therapeutic
levels of warfarin can predispose the individuals to over-anticoagulation and increased risk of life
threatening bleeding episodes [17,18]. The inter-individual variability in plasma levels of warfarin can
be partly explained by single nucleotide polymorphisms (SNPs) of two genes encoding for CYP2C9
and VKORC1 [17–20]. Presence of genetic variants CYP2C9*2 and CYP2C9*3 reduce the clearance
of S-warfarin can increase the risk of over-coagulation and bleeding episodes [17–19]. Furthermore,
VKORC1 genetic variants 1639 G>A and 1172 C>T increase warfarin sensitivity and are associated
with increased risk of bleeding episodes [17–19].
Accordingly, knowledge of patient specific pharmacogenomics of warfarin can aid the clinician
in appropriate dosing of warfarin in high risk cases. Previously conducted clinical trials revealed
substantial clinical benefit with genotype guided warfarin therapy with lower out of range International
Normalized Ratio (INR) values [21–24]. The Clinical Pharmacogenetics Implementation Consortium
(CPIC) was created to help translate the results of pharmacogenomics testing into guidelines for
appropriate dosage adjustments in patient specific clinical scenarios [24,25].
Pharmacogenomics of direct oral anticoagulants is currently a new area of research. Until now,
very few genome wide association studies (GWAS) have been done to unravel the relevant genetic loci
and genetic variants (SNPs) and their impact on drug metabolism and inter-individual variability of
DOACs [26]. Current prescribing trends reveal that DOACs comprised 56.5% of oral anticoagulant
prescriptions, with rivaroxaban most frequently prescribed, followed by apixaban and dabigatran,
from 2012–2015 in the United Kingdom [27]. According to retrospective analysis of Medicare Part,
D.; in 2015, DOACs claims comprised 31% of all anticoagulant claims, which showed a substantial
increase of 127% in DOAC usage as compared to 2013 [28].
Although DOACs have predictable pharmacokinetics and pharmacodynamics and do not require
routine coagulation monitoring per label, there have been recent reports of wider inter- individual
variability in their plasma and drug responses [29,30]. Although several factors such as age, race,
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gender, smoking, and diet can lead to inter-individual variability of DOACs, presence of common
genetic variants or drug-drug interactions may contribute to these differences [31].
This review article is to provide a brief overview of current approved indications, mechanism of
action, pharmacokinetics, pharmacodynamic side effects, antidotes, drug-drug interactions, and drug
gene interactions. The main purpose of this article is to focus on recently published pharmacogenomic
studies conducted that have looked into the relationship between SNPs of common genetic variants and
plasma drug levels of DOACs, namely dabigatran, rivaroxaban, apixaban, and edoxaban. Each drug
review is followed by a table summary of recently published research articles and their impact
on drug levels and clinical outcomes of all four DOACs. The discussed SNPs of genetic loci may
provide information regarding personalization of therapy based on patient specific genetic variants for
improving safety and efficacy of DOAC use in the general population.
2. Dabigatran
Dabigatran is a new direct oral anticoagulant agent, initially approved in Europe and later in
2010 by the Unites States Food and Drug Administration (FDA), for reducing the risk of stroke
in non-valvular atrial fibrillation (AF) [32–35]. Later in 2014, the drug label was expanded to
included prophylaxis against prevention of deep vein thrombosis and pulmonary thromboembolism
in patients undergoing hip replacement [33,36,37]. Dabigatran is a reversible competitive inhibitor
of thrombin that specifically inhibits both free and clot bound thrombin and thrombin induced
platelet activation [32,38,39]. Dabigatran is administered as dabigatran etexilate orally, which is
converted by esterases into the active form, dabigatran [32,39]. Major metabolites and metabolic
pathways are demonstrated (Supplemental Figure S1). Remarkable pharmacokinetic features of
dabigatran include rapid absorption, low bioavailability (3–7%), variable peak concentrations, attaining
steady state concentration in 2–3 days, bi-exponential distribution phase, volume of distribution
(50–70 L), 35% bound to plasma proteins, hepatic conjugation with glucuronide, and renal elimination
(80%) [2,32,38,40–42].
Reilly et al. reported that dabigatran plasma concentration is mainly dependent on factors such
as renal function, age, weight, and gender [43]. Additionally, the authors found that there was a
fivefold variation in peak and trough levels for dabigatran doses 110 ng and 150 mg in the Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial conducted in 18,113 patients [43].
Since 80% of dabigatran is excreted by the kidneys, its half-life and dosing is dependent on kidney
function and creatinine clearance [32,44]. The half-life of dabigatran ranges from 12–17 h and, it can
be prolonged to 15–35 h in cases of renal insufficiency [32,44]. Although dabigatran can prolong
prothrombin time (PT) and activated partial thromboplastin time (aPTT), these tests are not reliable
for measuring dabigatran drug concentrations as they have poor correlation and poor sensitivity [45].
According to the International Council for Standardization in Hematology (ICSH) recommendations,
liquid chromatography with tandem mass spectrometry (LC-MS/CS) is the gold standard test for
measuring all DOAC concentrations [45].
Prolongation of aPTT correlates with low to moderate plasma concentration of dabigatran but it
becomes less sensitive at supratherapeutic levels [46]. Thrombin Time (TT) is a very sensitive assay that
can be used to assess the anticoagulant effect of dabigatran, although a normal TT time is indicative
of minimal plasma levels of dabigatran [46,47]. In light of its favorable pharmacokinetic profile and
predictable anticoagulant dose response, routine coagulation monitoring is not required per drug label
in contrast to vitamin K antagonists [2,32,40,48].
Dabigatran usage was associated with low risk of dose dependent adverse effects such as
dyspepsia, hepatic impairment, and bleeding events, supporting its safety profile [40,48].
Hemostatic agents such as activated recombinant factor VII (rFVIIa) and activated prothrombin
complex concentrates (PCCa) may be used in the treatment of major bleeding episodes caused by
supratherapeutic levels of dabigatran, although their efficacy is not well established in previously
conducted clinical trials [32,38,40].
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Recently, a monoclonal antibody, idarucizumab, was shown to reverse dabigatran induced
anticoagulation by rapidly binding dabigatran and has been approved for dabigatran induced
life threatening bleeding episodes [15]. Pharmacokinetic drug-drug interactions of dabigatran
are mediated primarily by p-glycoprotein (p-gp), but not cytochrome P-450 enzymes [48,49].
Accordingly, caution should be exercised during the concomitant use of p-gp inducers such as
rifampicin/rifampin (decreased concentration) and p-gp inhibitors such as ketoconazole, quinidine,
amiodarone, and verapamil (increased concentration) with dabigatran [38,50]. Dabigatran and p-gp
inhibitors should not be administrated together, particularly in severe renal impairment, as it can lead
to high levels of dabigatran and life-threatening bleeding tendencies [38,50].
2.1. Pharmacogenomics
Dabigatran etelixate is an oral prodrug and is metabolized initially by intestinal carboxylesterase
(CES2) enzyme to its intermediate metabolite dabigatran ethyl ester (M2) [51,52]. Later, M2 is converted
to dabigatran (active form) by liver carboxylesterase (CES1) enzyme [51,52].
Bioavailability of dabigatran etelixate is influenced by the ABCB1 gene, which encodes for
p-glycoprotein (p-gp), an ATP dependent drug efflux transporter [29,30,53]. Even though routine
coagulation monitoring is not required for use of dabigatran, substantial inter-individual variation in
plasma concentration of dabigatran has been demonstrated. Several common genetic variants of CES1
and ABCB1 genetic loci have been identified in genome wide analyses, which may potentially account
for some of the inter-individual variation in dabigatran plasma levels. Pare et al. conducted a genome
wide pharmacogenomic analysis to characterize various CES1 and ABCB1 genetic variants associated
with trough and peak levels of dabigatran [29].
2.2. CES1 Gene
Genetic variants of the liver carboxylesterase (CES1) gene, which catalyzes the conversion of M2
metabolite of dabigatran to active form, can regulate the pharmacokinetics of dabigatran.
One of the most important characterized is the CES1 genetic variant SNP rs2244613 [29]. CES1 SNP
rs2244613 is associated with decreased dabigatran trough concentration and decreased risk of bleeding,
a finding that may potentially impact efficacy of the drug during clinical use [29,53]. In general,
high trough concentrations are more likely predictive of bleeding episodes as compared to high peak
levels because lower trough levels can ensure intermittent strengthening of hemostatic plug formation
at the site of vessel damage, thus resulting in less bleeding episodes [29]. None of the SNPs identified
in this pharmacogenetic study demonstrated significant association with increased pro-thrombotic risk
and no increase in incidence of ischemic events or systemic embolism [29]. CES1 rs2244613 carriers
were shown to have lower risk of bleeding episodes with dabigatran as compared with warfarin
and non-carriers [53]. Additionally, minor allele carriers of CES1 rs2244613 were also shown to have
less bleeding episodes with lower doses (110 mg twice daily) as compared to higher doses (150 mg
twice daily) [53]. Patients who are heterozygous for SNP rs2244613 have been shown to have 15%
lower risk of bleeding, whereas patients who are homozygous for SNP rs2244613 demonstrated 28%
lower incidence of bleeding with dabigatran treatment as compared to warfarin [54]. There were no
reports of increased adverse thrombotic episodes in patients with CES1 SNP rs2244613, who had lower
bleeding risk among subjects studied in the RE-LY trial [29]. It has been reported that lower trough
levels of dabigatran leads to formation of more stable hemostatic formation that reduces the risk of
bleeding tendencies with CES1 SNP rs2244613 [29].
In patients receiving dabigatran prophylaxis after orthopedic surgery, higher trough levels were
associated with CC genotype of CES1 rs2244613 (34.6 (32.2–36.9) ng/mL), whereas lowest trough
levels were associated with AA genotype of CES1 rs2244613 (17.1 (12.0–25.4) ng/mL), although these
findings were not statistically significant [52].
Since CES1 genetic locus has more than 2000 genetic variants, other mutants were also
characterized to assess their effect on dabigatran peak and trough concentrations [51,54].
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Another CES1 SNP (rs8192935) has been associated with variability of both peak and trough
concentrations of dabigatran with no clinical impact on bleeding risk [29,53]. The presence of CES1
SNP rs819295 was associated with a 12% decrease in peak plasma levels of dabigatran [54]. It has been
suggested that linkage disequilibrium of CES1 rs8192935 with unknown allelic variants may contribute
to alterations in plasma levels and may regulate dabigatran anticoagulant efficacy [30]. In patients
with atrial fibrillation receiving dabigatran for anticoagulant prophylaxis, CC genotype of CES1 SNP
rs8192935 was associated with higher plasma levels of dabigatran (86.3 ng/mL), as compared to T
genotype (62.1 ng/mL) [30,52].
CES1 SNP rs71647871 (or G14E) loss of function variant attenuates the metabolism of dabigatran
and its metabolites (M1 and M2) [51]. Specifically, mean activation rates of dabigatran, M1, and M2 in
the carriers of the CES1 G14E mutant were lower at 53%, 43%, and 37%, respectively, as compared to
non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were not associated with dabigatran
levels in this study [51]. Of note, metabolism of dabigatran and its metabolites were significantly
higher in female livers as compared to male livers [51].
2.3. ABCB1
One of the most important ABCB1 genetic variants is rs1045642, which was found to be
significantly associated with peak dabigatran concentration and increased incidence of bleeding
episodes [52]. Particularly, patients with TT genotype of rs1045642 experienced higher peak dabigatran
levels and higher risk of bleeding (relative risk: 1.72; 95% confidence interval: 0.92–3.22) than patients
with CC genotype of rs1045642, although this is not a significant finding [52]. The peak plasma
concentration was higher in subjects with TT genotype (291.8 (193.6–345.0) ng/mL) than in subjects
with CC genotype (124.1 (79.9–177.7) ng/mL) (p = 0.008), but there was no significant difference
in trough levels [52]. Another well studied ABCB1 variant (rs4148738) has been associated with
up to 12% increase in peak concentration of dabigatran without significant impact on bleeding
risk [29,53]. In patients receiving dabigatran for venous thromboembolism prophylaxis after total knee
replacement surgery, equilibrium peak levels were 218.7 (143.4–310.7) ng/mL for GG genotype and
130.7 (102.2–249.1) ng/mL for GA genotype with respect to ABCB1 rs4148738 polymorphism [52]. Third,
ABCB1 variants rs2032582 (C.2677G>A/T), rs1045642 (c.3435C>T), and rs1128503 (1235C>T) were also
studied. These three SNPs occur as haplotype together and they can be related to each other by linkage
disequilibrium [55]. There appears to be limited impact of homozygous, heterozygous, and wild type
variants ABCB1 haplotype 1235–2677–3455 on pharmacokinetics of dabigatran [55]. A summary of
pharmacogenetic studies performed with dabigatran is provided in Table 1.
Table 1. Common genetic variants associated with pharmacodynamics and pharmacokinetics
of dabigatran.
Peak Levels SNP Locus Function p-Value Change(Concentration) Clinical Outcome Ref. Year
rs8192935 CES1 Intron 3.2 × 10−8
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Bleeding 
[29] 2013 
 G14E CES1 Intron 0.018 
 
Not test [51] 2016 
 rs8192935 CES1 Intron 0.023 
 
ot tested [30] 2016 
 rs2244613 CES1 Intron 0.04 
 
ot tested [30] 2016 
No significant difference [52] 2018
rs71647871
(G143E) CES1 Intron 0.018
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been suggested that linkage disequilibrium of CES1 rs8192935 with unknown allelic variants may 
contribute to alterations in plasma levels and may regulate dabigatran anticoagulant efficacy [30]. In 
patients with atrial fibrillation receiving dabigatran for anticoagulant prophylaxis, CC genotype of 
CES1 SNP rs8192935 was associated with higher plasma levels of dabigatran (86.3 ng/mL), as 
compared to T genotype (62.1 ng/mL) [30,52]. 
CES1 SNP rs71647871 (or G14E) loss of function variant attenuates the metabolism of dabigatran 
and its metabolites (M1 and M2) [51]. Specificall , mean activation rates of dabigatran, M1, and M2 
in the carriers of the CES1 G14E mutant were lower at 53%, 43%, and 37%, respectively, as compared 
to non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were not associated with 
dabigatra  levels in this study [51]. Of note, metabolism of dabigatran and its metabolites were 
significantly higher in female livers as compared to male livers [51]. 
2.3. ABCB1 
One of the most important ABCB1 genetic variants is rs1045642, which was found to be 
significantly associated with peak dabigatran concentration and increased incidence of bleeding 
episodes [52]. Particularly, patients with TT genotype of rs1045642 experienced higher peak 
dabigatran levels and higher risk of bleeding (relative risk: 1.72; 95% confidence interval: 0.92–3.22) 
than patients with CC genotype of rs1045642, although this is not a significant finding [52]. The peak 
plasma concentration in subjects with TT genotype was 291.8 (193.6–345.0) ng/mL and 124.1 (79.9–
177.7) ng/mL in subjects with CC genotype [52]. Another well studied ABCB1 variant (rs4148738) has 
been associated with up to 12% incr ase in peak concentration of dabigatran without significant 
impact on bleeding risk [29,53]. In patients receiving dabigatran for venous thromboembolism 
prophylaxis after total knee replacement surgery, equilibrium peak levels were 218.7 (143.4–310.7) 
ng/mL for GG genotype and 130.7 (102.2–249.1) ng/mL for GA genotype with respect to ABCB1 
rs4148738 polymorphism [52]. Third, ABCB1 variants rs2032582 (C.2677G>A/T), rs1045642 
(c.3435C>T), and rs1128503 (1235C>T) were also studied. These three SNPs occur as haplotype 
together and they can be related to each other by linkage disequilibrium [55]. There appears to be 
limited impact of homozygous, heterozygous, and wild type variants ABCB1 haplotype 1235–2677–
3455 on pharmacokinetics of dabigatr n [55]. A summary of pharmacogenetic studies performed 
with dabigatran is provided in Table 1. 
Table 1. Common genetic variants associated with pharmacodynamics a d pharmacoki etics of 
dabigatran. 
Peak 
Levels 
SNP Locus Function p-Value Change 
(Concentration) 
Cl nical Ou com  Ref. Year 
 rs8 92935 CES1 Intron 3.2 × 10−8 
 No significant association 
with clinical events [29] 2013 
 rs4148738 ABCB1 Intron 8.2 × 10−8 
 No significant association 
with clinical events 
[29] 2013 
 rs1045642 ABCB1 Intron 0.008 
 
No signific nt difference [52] 2018 
 
rs71647871 
(G143E) 
CES1 Intron 0.018 
 
Not tested [51] 2016 
 2677–3455 ABCB1 Intron 0.58 
 
Not tested [55] 2016 
Trough 
Levels 
SNP Locus Function p-Value Change Clinical Outcome Ref. Year 
 rs2244613 CES1 Intron 1.2 × 10−8 
 
Bleeding [29] 2013 
 G14E CES1 Intron 0.018 
 
Not tested [51] 2016 
 rs8192935 CES1 Intron 0.023
 
Not tested [30] 2016 
 rs2244613 CES1 Intron 0.04 
 
Not tested [30] 2016 
Not tested [51] 2016
2677–3455 ABCB1 Intron 0.58
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been suggested that linkage disequilibrium of CES1 rs8192935 with unknown allelic variants may 
contribute to alterations in plasma levels and may regulate dabigatran anticoagulant efficacy [30]. In 
patients with atrial fibrillation receiving dabigatran for anticoagulant prophylaxis, CC genotype of 
CES1 SNP rs8192935 was associated with higher plasma levels of dabigatran (86.3 ng/mL), as 
compared to T genotype (62.1 ng/mL) [30,52]. 
CES1 SNP rs71647871 (or G14E) loss of function variant attenuates the metabolism of dabigatran 
and its metabolites (M1 and M2) [51]. Specifically, mean activation rates of dabigatran, M1, and M2 
in the carriers of the CES1 G14E mutant were lower at 53%, 43%, and 37%, respectively, as compared 
to non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were not associated with 
dabigatran levels in this study [51]. Of note, metabolism of dabigatran and its metabolites were 
significantly higher in female livers as compared to male livers [51]. 
2.3. ABCB1 
One of the most iportant ABCB1 genetic variants is rs045642, which ws found to be 
significantly associated with peak dabigatran concentration and increased incidence of bleeding 
episodes [52]. Particularly, patients with TT genotype of rs1045642 experienced higher peak 
dabigatran levels and higher risk of bleeding (relative risk: 1.72; 95% confidence interval: 0.92–3.22) 
than patients with CC genotype of rs1045642, although this is not a significant finding [52]. The peak 
plasma concentration in subjects with TT genotype was 291.8 (193.6–345.0) ng/mL and 124.1 (79.9–
177.7) ng/mL in subjects with CC genotype [52]. Another well studied ABCB1 variant (rs4148738) has 
been associated with up to 12% increase in peak concentration of dabigatran without significant 
impact on bleeding risk [29,53]. In patients receiving dabigatran for venous thromboembolism 
prophylaxis after total knee replacement surgery, equilibrium peak levels were 218.7 (143.4–310.7) 
ng/mL for GG genotype and 130.7 (102.2–249.1) ng/mL for GA genotype with respect to ABCB1 
rs4148738 polymorphism [52]. Third, ABCB1 variants rs2032582 (C.2677G>A/T), rs1045642 
(c.3435C>T), and rs1128503 (1235C>T) were also studied. These three SNPs ccur ashaplotype
together and they can be related to each other by linkage disequilibrium [55]. There appears to be 
limited impact of homozygous, heterozygous, and wild type variants ABCB1 haplotype 1235–2677–
3455 on pharmacokinetics of dabigatran [55]. A sumary of pharmacogenetic studies performed 
with dabigatran is provided in Table 1. 
Table 1. Common genetic variants associated with pharmacodynamics and pharmacokinetics of 
dabigatran. 
Peak 
Levels 
SNP Locus Function p-Value 
Change 
(Concentration) 
Clinical Outcome Ref. Year 
 rs8192935 CES1 Intron 3.2 ×10
−8
 
 
Nosignificant association
with clinical events 
[29] 2013 
 rs4148738 ABCB1Intron 8.2 ×10
−8
 
 
Nosignificant association 
with clinical events 
[29] 2013 
 rs1045642 ABCB1 Intron 0.008 
 
No significant difference [52] 2018 
 
rs71647871 
(G143E) 
CES1 Intron 0.018 
 
Not tested [51] 2016 
 2677–3455 ABCB1 Intron 0.58 
 
Not tested [55] 2016 
Trough 
Levels 
SNP Locus Function p-Value Change Clinical Outcome Ref. Year 
 rs2244613 CES1 Intron 1.2 × 10
−8
 
 
Bleeding 
[29] 2013 
 G14E CES1 Intrn 0.018 
 
Not tested [51] 2016 
 rs8192935 CES1 Intron 0.023 
 
Not tested [30] 2016 
 rs2244613 CES1 Intron 0.04 
 
Not tested [30] 2016 
Not tested [55] 2016
Trough Levels SNP Locus Function p-Value Change Clinical Outcome Ref. Year
rs2244613 CES1 Intron 1.2 × 10−8
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been suggested that linkage disequilibrium of CES1 rs8192935 with unknown allelic variants may 
contribute to alterations in plasma levels and may regulate dabigatran anticoagulant efficacy [30]. In 
patients with atrial fibrillation receiving dabigatran for anticoagulant prophylaxis, CC genotype of 
CES1 SNP rs8192935 was associated with higher plasma levels of dabigatran (86.3 n /mL), as 
compared to T genotype (62.1 ng/mL) [30,52]. 
CES1 SNP rs71647871 (or G14E) loss of function variant attenuates the metabolism of dabigatran 
and its metabolites (M1 a d M2) [51]. Specifically, mean activation rates of dabigatra , M1, and M2 
in the carriers of the CES1 G14E mutant were lower at 53%, 43%, and 37%, respectively, as compared 
to non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were not associated with 
dabigatran levels in this study [51]. Of not , metabolism of dabigatran and its etabolites wer  
 higher in female livers as comp red to male livers [51]. 
2.3. ABCB1
One of the most important ABCB1 genetic variants is rs1045642, whic  was found to be 
significantly associated with peak dabigatran concentration and increased incidence of bleeding 
episodes [52]. Particularly, patients with TT genotype of rs1045642 experienced higher peak 
dabigatran levels and higher risk of bleeding (relative risk: 1.72; 95% confidence interval: 0.92–3.22) 
than patients with CC genotype of rs1045642, although this is not a significant fi di g [52]. The peak 
plasma concentration in subjects with TT genotype was 291.8 (193.6–345.0) ng/mL and 124.1 (79.9–
177.7) ng/mL in subjects with CC ge o ype [52]. Another well studied ABCB1 varia t (rs4148738) has 
been associated with up to 12% increase in peak concentration of dabigatran without significant 
impact on bleeding risk [29,53]. In patien s receiving dabigatr n for venous thr mboembolism 
prophylaxis fter total knee replac ment surgery, equilibrium peak levels were 218.7 (143.4–310.7) 
ng/mL for GG genotype and 130.7 (102.2–249.1) ng/mL for GA genotype with respect to ABCB1 
rs4148738 polymorphism [52]. Third, ABCB1 variants rs2032582 (C.2677G>A/T), rs1045642 
(c.3435C>T), and rs1128503 (1235C>T) were also studied. These three SNPs occur s haplotype 
together and they can be related to each other by linkage disequilibrium [55]. There appears to be 
limited impact of homozygous, het rozygous, and wild type variants ABCB1 haplotype 1235–2677–
3455 on pharmacokinetics of dabigatran [55]. A summary of pharmacogenetic studies performed 
with dabigatran is provided in Table 1. 
Table 1. Common genetic variants associated with pharmacodynamics and pharmacokinetics of 
dabigatran. 
Peak Change 
(Concentration) 
8192935 3
 No significant association 
with clinical events 
 rs4148738 ABCB1  8.2 × 10−8 
 No significant association 
with clinical events 
29  3 
 rs1045642 ABCB1 Intron 0.008 
 
No significant difference [52] 2018 
 
rs71647871 
(G1 3E) 
CES1 Intron 0.018 
 
Not tested [51] 2016 
 2677–3455 ABCB1 Intron 0.58 
 
Not test d [55] 2016 
Trough 
Levels 
SNP Locus Function p-Value Change Clinical Outcome Ref. Year 
 rs2244613 CES1 I tro  1.2 × 10−8 
 
Bleeding [29] 2013 
 G14E CES1 Intron 0.018 
 
Not tested [51] 2016 
 rs8192935 CES1 I tron 0.023 
 
Not ested [30] 2016 
 rs2244613 CES1 Intron 0.04 
 
Not tested [30] 2016 
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bee  suggested t at linkage disequilibrium of CES1 rs8192935 with unknown llelic variants may 
contribute to alterations i  plasma levels and m y regulate dabiga ran anticoagulant efficacy [30]. In 
pat ents with atrial fibrillat on eceiving dabigatr  fo  anticoagulant prophylaxis, CC genotype of 
CES1 SNP r 8192935 was associated with higher pl sma levels f dabigatran (86.3 ng/mL), as 
c m ared to T genotype (62.1 ng/mL) [30,52]. 
CES1 SNP rs71647871 (or G14E) loss of function variant attenuates the metabolism of dabigatran 
and its metabolites (M1 and M2) [51]. Specifically, m an activation rates of dabigatra , M1, an  M2 
in the carriers of the CES1 G14E mu ant were lower at 53%, 43%, and 37%, res ectively, as compared 
to non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were not associated with 
dabigatran levels in this study [51]. Of n te, met bolism of dabigatran and its metabolites were 
s g i ican ly higher in female livers s compare  to male livers [51]. 
2.3. ABCB1 
One f the most important ABCB1 genetic variants s rs1045642, which was found to be 
s gnifican ly associa ed with peak dabigatran co centration and increased incidence of bleeding 
ep sodes [52]. Particularly, patients with TT genotype of rs1045642 experienced higher peak 
dabigatran levels and igher risk of bleeding (relative risk: 1.72; 95% confidence interval: 0.92–3.22) 
t an patients with CC genotype f rs1045642, although this is  a significant finding [52]. The peak 
plasma concentration in subjects with TT genotype was 291.8 (193.6–345.0) ng/mL and 124.1 (79.9–
177.7) ng/mL in subj cts with CC genotyp  [52]. Another well studied ABCB1 variant (rs4148738) has 
been associated with up to 12% increase in peak concen tion of dabi atran without significant 
impact on bleedi g risk [29,53]. In patients rece ving dabiga ran for ven u  thromboembolism 
prophylaxis after otal knee replacement surgery, equilibrium peak levels were 218.7 (143.4–310.7) 
ng/mL for GG genotype and 130.7 (102.2–249.1) ng/mL for GA genotype with respect to ABCB1 
rs4148738 polymorphism [52]. Th rd, ABCB1 variants rs2032582 (C.2677G>A/T), rs1045642 
(c.3435C>T), and rs1128503 (1235C>T) were also studied. The e hree SNPs occur as haplotype 
together and they c n be related to e ch other by linkage disequilibrium [55]. There appears to be 
limited impact of hom zygous, heteroz gous, and wild type variants ABC 1 haplotype 1235–2677–
3455 on pharmacokinetics of dabigatr n [55]. A summary of pharmacogenetic studies performed 
with dabigatr  i  provided in Table 1. 
Table 1. Common genetic var ants associated with pharmacodynamics and pharmacokinetics of 
dabigatran. 
Peak 
evel  
SNP Locus Function p-Value Change 
(Concentr tion) 
Clinical Outcome Ref. Year 
 rs8192935 CES Intron 3.2 × 10−8 
 No significant a soci tion 
with clinical events [29] 2013 
 rs4148738 A CB1 Intron 8.2 × 10−8 
 No significant association
with clinical events 
[29] 2013 
 rs1045642 ABCB1 Intron 0.008 
 
No significant difference [52] 2018 
 
rs71647871 
(G143E) 
CES1 Intron 0.018 
 
N t tested [51] 2016 
 2677–3455 ABCB1 Intron 0.58 
 
Not tes ed [55] 2016 
Trough 
Levels 
SNP Locus Function p-Value Change Clinical Outcome Ref. Year 
 rs2244613 CES1 Intr  1.2 × 10−8 
 
Bleeding [29] 2013 
 G14E CES1 Intron 0.018 
 
Not tested [51] 2016 
 rs8192935 CES1 Intron 0.023 
 
Not t sted [30] 2016 
 rs2244613 CES1 Intron 0.04 
 
Not ested [30] 2016 
Bleeding [29] 2013
G14E CES1 Intron 0.018
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been suggested that linkage d sequilibrium of CES1 rs81 2935 with unknown allelic variants may 
contribute to alterations in plasma levels and may regulate dabig tran anticoagulant effica y [30]. In 
patients with atrial fibr llati n receiving dabiga ran for anticoagulant prophylaxis, CC ge otype of
CES1 SNP rs8192935 wa  associate  with higher pla a level  of d bigatran (86.3 ng/mL), a
compared to T enotyp  (62.1 ng/mL) [30,52]. 
CES1 SNP r 71647871 (or G14E) loss of function va ant attenuates the m tabolism of dabigatran
and its metabol es (M1 and M2) [51]. Specific lly, mean activation rates of dabigatran, M1, and M2
in the carriers of the CES1 G14E mutant wer  l wer at 53%, 43%, and 37%, respectively, as compared 
to non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were not associated with
dabig tran levels in this study [51]. Of note, metabolism of dabigatran nd its metabol tes were
significantly higher in female livers as compared to male livers [51]. 
2.3. ABCB1 
O e of the most important ABCB1 genetic variants i  rs1045642, which was found to be 
significantly associated with peak dabigatran con e tration a d increased i cidence of bleeding
episodes [52]. Particularly, patients with TT g notype of rs1045642 experienced higher peak 
dabigatr n levels and high r risk of bleeding (relative risk: 1.72; 95% confidenc  interval: 0.92–3.22) 
than patients with CC g notype of rs104564 , although this is not a significant finding [52]. The peak 
plasma concentration in subjects with TT genotype was 291.8 (193.6–345.0) ng/mL and 124.  (79.9–
177.7) ng/mL i  subjects with CC genotype [52]. Another well studied ABCB1 variant (rs4148738) has 
been associated with up to 12% increase in peak concentration of dabigatran without significant 
i pact on bleeding risk [29,53]. In patient  receiving dabig tr  for venous thromboembolism 
prophylaxis after total knee replacement surgery, equilibrium e k levels were 218.7 (143.4–310.7) 
ng/mL for GG genotype and 130.7 ( 02.2–249.1) ng/mL for GA genotype with respect to ABCB1 
rs4148738 polymorphism [52]. Third, ABCB1 variants rs2032582 (C.2677G>A/T), rs1045642 
(c.3435C>T), and rs1128503 (1235C>T) were also studied. These three SNPs occur as haplotype 
together and they can be related to each other by linkage disequilibrium [55]. Th re appears to be 
limited impact of homozygous, heterozygous, and wild type variants ABCB1 haplotype 1235–2677–
3455 on pharmacokinetics of dabigatran [55]. A summary of pharmacogenetic studies performed 
with dabigatran is provided in Table 1. 
Table 1. Common genetic variants associated with pharmacodynamics and pharmacokinetics of 
dabigatran. 
Peak 
Levels 
SNP Locus Function p-Value Change 
(Concentration) 
Clinical Outcome Ref. Year 
 rs8192935  I tr  3.2 × 10−8 
 o significant association 
ith clinical events [29] 3 
 4 487 8 ABCB1  8.2 × 10−8 
 No significant association 
with clinical events 
29  3 
10 5 42 ABCB1 0.008 
 
No significant difference 52 8
 
rs71647871 
(G143E) 
CES1 Intron 0.018 
 
ot tested [51] 2016 
 2677–3455 ABCB1 Intron 0.58 
 
Not tested [55] 2016 
Trough 
Levels 
SNP Locus Fu ction p-Value Change Clinical Outcome Ref. Year 
 rs2244613 S1 I tro  1.2 × 10−8 
 
Bleeding [29] 2013 
 G14E 1 Intr  0.018 
 
t teste  [51] 2016 
 rs8192935 1 I tr  0.023 
 
t teste  [30] 2016 
 rs2244613 CES1 Intron 0.04 
 
Not tested [30] 2016 
No test d [51] 2016
rs8192935 CES1 Intron 0.0 3
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been suggested that link ge disequilibrium of CES1 rs8192935 with unkno n allelic varia ts m y
ntribute alterations in plasma levels and may regulate dabigatran anticoagulant efficacy [30]. In 
patients with atrial fibrillati n receiving dabiga ra fo  icoag la t p ophylaxis, CC genotype f
CES1 SNP rs8192935 was ass c ated with higher plasma leve s of dabi atr n (86.3 ng/mL), as
compared to T geno ype (62.1 ng/mL) [30,52]. 
CES1 SNP rs71647871 (or G14E) loss of function variant attenuates the metab lism f dabigatran
and its metabolites (M1 and M2) [51]. Specifically, mean activation r es of dab g tr n, M1,  M2
in the rriers of the CES1 G14E mut nt were lower at 53%, 43%, and 37%, respe tiv ly, as compared 
to non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were not associat d with 
l l  i  t is study [51]. Of note, me abolism of dabigatra  and its metabolites were
sig ificantly higher in female livers as compared to male livers [51]. 
2.3. ABCB1 
One of the most mportant ABCB1 g netic variants is rs1045642, whi h was f un  to be
sig ificantly associ ted wi h peak dabigatran concentration and increased incidence o bl eding
epi odes [52]. Particul rly, patients with TT geno ype of rs1045642 experience  higher peak 
dabigatran level  and higher risk of bl ding (relative risk: 1.7 ; 95% confid nce int rval: 0.92–3.22)
tha  patients with CC gen typ  of rs1045642, although this is n t  signif c nt finding [52]. The peak
plasm  concentrati n n subjects with TT genotype was 291.8 (193.6–345.0) ng/mL and 124.1 (79.9–
177.7) ng/mL in subjects with CC geno ype [52]. Another well studied ABCB1 varia t (rs4148738) has
been ass ciated with up to 12% increase in peak concentration of dabigatran without significant
impact on bleeding risk [29,53]. In atients recei ing dabigatran fo  venou  thromboembolism
prophylaxis after total knee replacement surgery, eq il brium peak levels were 218.7 (143.4–310.7)
ng/mL for GG genotyp  and 130.7 (102.2–249.1) ng/mL for GA genotype with r spect to ABCB1
rs4148738 polymorphism [52]. Third, ABCB1 va iants r 20325 2 ( .2677G>A/T), rs1045642 
(c.3435C>T), and rs1128503 (1235C>T) were also studied. These three SNPs occ  as haplo ype
together and they can be rel ted to each other by linka e disequilibrium [55]. There appears to be 
limited impact of homozygous, heterozygous, and wild type variants ABCB1 haplotype 1235–2677–
3455 on pharmacokinetics of dabigatran [55]. A summary of ph rmacogenetic studies perf rmed 
with dabigatran is provided in Table 1. 
Table 1. Common genetic variants associat d with pharmacodynamics and pharmacokinetics of 
dabigatran. 
Peak 
Levels 
SNP Locus Function p-Value Chan e 
(Concentration) 
Cli ical Outcome Ref. Year 
 rs8192935 CES1 Intron 3.2 × 10−8 
 o significant association 
ith clinical ev nts [29] 2013 
 rs4148738 ABCB1 Intron 8.2 × 10−8 
 No significant association 
with clinical events 
[29] 2013 
 rs1045642 ABCB1 Intron 0.008 
 
No significant difference [52] 2018 
 
rs71647871 
(G143E) 
CES1 I tron 0.018 
 
ot tested [51] 2016 
 2677–3455 ABCB1 I tron 0.58 
 
Not ested [55] 2016 
Trough 
Levels 
SNP Locus Function p-Value Change Clinical Outcome Ref. Year 
 rs2244613 CES1 I tron 1.2 × 10−8 
 
Bleeding [29] 2013 
 G14E CES1 Intron 0.018 
 
Not tested [51] 2016 
 rs8192935 1 I tr  0.023 
 
t teste  [30] 2016 
 rs2244613 CES1 Intron 0.04 
 
Not tested [30] 2016 
Not tested [30] 2016
rs2244613 CES1 Intron 0.04
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been suggested that link ge isequilibrium of CES1 rs8192935 with unknown all lic variants m y
ntribute altera ons in plasma levels and may regulate dabigatran anticoagulant efficacy [30]. In
p tients with atrial fibr llati n receiving dabiga r fo  icoag lant prophylax s, CC genotype of
CES1 SNP rs8192935 was associated with hig er plasma levels of dabigatran (86.3 ng/mL), as
compared to T gen type (62.1 ng/mL) [30,52]. 
CES1 SNP rs71647871 (or G14E) loss of function variant attenuates the met b lism f dabigatran
and its met bolites (M1 and M2) [51]. Sp c fically, mean activation r es of d b gatran, M1, and M2
n the rriers of the CES1 G14E mut nt w re lower at 53%, 43%, and 37%, respectively, as compared
to non-carriers (100%) [51]. CES1 variants rs2244613 and rs8192935 were ot associated with
dabigatran levels in this study [51]. Of note, metabolism of dabigatran and its metabolites were
significantly higher in fe ale livers as compared to male livers [51]. 
2.3. ABCB1
One of th  most mportant ABCB1 gen tic variants is rs1045642, whi h was found to be
si ificantly associated wi h peak dabigatran co centrati n and increas d incid nc  of bl eding
epi odes [52]. Particularly, patients with TT genotype of rs104 642 experienced higher peak 
dabigatran level  and higher risk f bleeding (relative risk: 1.72; 95% confidence i terval: 0.92–3.22)
tha  patie ts with CC genotyp  of rs1045642, although this is n t a signif c nt finding [52]. The peak
plasma concentrati n n subjects with TT genotype was 291.8 (193.6–345.0) ng/mL and 4.1 (79.9
177.7) g/mL in subjects with CC genotype [ 2]. Another well studied ABCB1 varia t (rs4148738) has
been ass ciated with up to 12% increase in peak concentration of dabigatran without significant
impact on bleeding risk [29,53]. In patients recei ing dabigatran for venous hromboembolism
prophylaxis after t tal knee repl c me t surgery, eq il brium pe k levels were 218.7 (143.4–310.7)
ng/mL for GG genotyp  and 130.7 (10 .2–249.1) ng/mL for GA genotype with r spect to ABCB
rs4148738 polymorphism [52]. Third, ABCB1 variants rs2032582 ( .2677G>A/T), rs1045642 
(c.3435C>T), and rs1128503 (1235C>T) were also studi d. These three SNPs occ r as haplotype
together and they can be related to each other by linkage disequilibrium [55]. There appears to be 
limited impact of homozygous, heterozygous, and wild type variants ABCB1 haplotype 1235–2677–
3455 on pharmacokinetics of dabig r n [55]. A summary of ph rmacogenetic studies perf rmed 
with dabigatran is provided in Table 1. 
Table 1. Common genetic variants associated with pharmacodynamics and pharmacokinetics of 
dabigatran. 
Peak 
Levels 
SNP Locus Function p-Value Change 
(Concentration) 
Cli ical Outcome Ref. Year 
 rs8192935 CES1 Intron 3.2 × 10−8 
 o signific n  ssociation 
ith cli ical ev nts [29] 2013 
 rs4148738 ABCB1 Intron 8.2 × 10−8 
 No significant association 
with cli ical vents 
[29] 2013 
 rs1045642 ABCB1 I tron 0.008 
 
No significant difference [52] 2018 
 
rs7164787  
(G1 3E) 
CES1 Intron 0.018 
 
ot tested [51] 2016 
 2677–3455 ABCB1 In ron 0.58 
 
Not tested [55] 2016 
Trough 
Levels 
SNP Locus Fu ction p-Value Change Clinical Outc me Ref. Year 
 rs2244613 S1 I tro  1.2 × 10−8 
 
Bleeding [29] 2013 
 G14E CES1 Intron 0.018 
 
Not tested [51] 2016 
 rs8192935 1 I tr  0.023 
 
t teste  [30] 2016 
 rs2244613 CES1 Intro  0.04 
 
Not tested [30] 2016 
Not tested [30] 2016
Peak and trough levels of Dabigatran and cli ical outcomes associated with gene loci an th ir si gle nucleotide
polymorphisms (SNPs) in recentl conducted linical studies.
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3. Rivaroxaban
Rivaroxaban is approved for use in non-valvular atrial fibrillation, treatment of deep vein
thrombosis, pulmonary embolism, cardiovascular disease, as well as prevention of thromboembolism
after orthopedic surgery [56,57]. The principal mechanism of action of rivaroxaban is through
inhibition of factor Xa, resulting in a blockade of intrinsic and extrinsic coagulation pathways [58–60].
Rivaroxaban is a small molecule oxazolidinone that specifically binds to S1 and S4 pockets of factor
Xa [58]. It has 10,000 times more selectivity than any other related serine proteases and binds to free
and clot bound factor Xa [58]. Some of the important pharmacokinetic properties of rivaroxaban
include rapid absorption, 100% bioavailability, 90% protein bound, 1.46 L volume of distribution,
5–9 h half-life, and elimination through renal and fecal routes [57,59–61]. Even though bioavailability
of 100% has been reported by some previous authors, it varies according to drug dosage and food
administration. The bioavailability of rivaroxaban depends on the dose with 10 mg achieving 80–100%
bioavailability whereas 20 mg dose leads to 66% bioavailability [61]. Co-administration of food with
15–20 mg rivaroxaban dose resulted in higher bioavailability and substantial increase in area under
curve (AUC) and maximal plasma concentration (Cmax) [61,62].
Rivaroxaban is the main active form, with onset of action and peak plasma concentration
occurring within 1–4 h [57–59,62,63]. Major metabolites and metabolic pathways are demonstrated
in Supplemental Figure S2. Maximum anticoagulant efficacy is achieved within 1–4 h and its antiXa
activity returns to baseline in 24–48 h [63]. Rivaroxaban dosing at 5–80 mg can result in 20–80%
inhibition of factor Xa activity [57–59].
Area under curve (AUC) and maximal plasma concentration of rivaroxaban are substantially
increased in renal impairment, hepatic impairment, and in patients older than 75 years [57–59,62,63].
Major bleeding episodes caused by supratherapeutic levels of rivaroxaban may be treated with
discontinuation of therapy, PCCa, and andexanet alpha [54,64,65]. Andexanet alpha is FDA approved
for treatment of life threating and uncontrolled bleeding episodes with rivaroxaban, but it is associated
with adverse effects such as deep vein thrombosis, pulmonary embolism, myocardial infarction,
and ischemic stroke [16].
Drug-drug interactions of rivaroxaban are mediated by CYP450 enzymes and p-gp [56,57,60].
Particularly, strong inhibitors of CYP450 enzymes and p-gp should be avoided in combination with
rivaroxaban as they may increase the plasma concentration and may lead to increased risk of bleeding
tendencies [56,57,60,61]. Moderate inhibitors of CYP450 enzymes and p-gp can be administrated in
combination with rivaroxaban.
Particularly in high risk patients such as those with renal failure, bleeding complications, stroke
and prior to major surgery, accurate measurement of peak and trough levels can be performed through
high performance liquid chromatography-mass spectrography (HPLC-MS) which is only available in
a few laboratories [66]. According to International Council for Standardization in Hematology (ICSH)
recommendations, laboratory assessment of rivaroxaban can be accurately performed with LC/MS-MS
(liquid chromatography with tandem mass spectrometry) and drug calibrated anti-FXa, but not PT
and aPTT as they are not reliable for measuring therapeutic drug concentrations [45].
3.1. Pharmacogenomics
As previously described, rivaroxaban is metabolized by CYP450 isoenzymes (CYP3A4, CYP2C8
and CYP2J2), p-gp, and the efflux transporter breast cancer resistance protein (BRCP) [24,67,68]. Strong
inducers of CYP3A4 such as rifampicin/rifampin, carbamazepine, phenobarbital, and phenytoin
should not be co-administered with rivaroxaban as they result in a decrease in AUC and
attenuated pharmacodynamics effects [60,61,69]. Conversely, co-administration of rivaroxaban
with strong CYP3A4 and p-gp inhibitors such as ketoconazole, itracomazole, voriconazole,
posaconazole and ritonavir can result in an increase in AUC, Cmax, and increased risk of bleeding
tendencies [60,61,69]. Moderate CYP3A4 and p-gp inhibitors such as erythromycin and clarithromycin
can be co-administered with rivaroxaban as their clinical impact is not clearly defined.
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3.2. ABCB1
ABCB1 gene polymorphisms, which encode for p-gp, were investigated in only a few clinical
studies to assess whether they account for differences in pharmacokinetics of rivaroxaban [55].
P-glycoprotein and BRCP are mainly responsible for active renal secretion of rivaroxaban [67].
There are more than 100 polymorphisms of ABCB1, among which rs2032582 (C.2677G>T) and rs1045642
(C.3435C>T) have been shown to affect rivaroxaban metabolism [54,55,67]. SNPs (C.2677G>T) and
(C.3435C>T) exhibit linkage disequilibrium and are frequently documented to exist as haplotypes.
The frequency of TT haplotype in the Caucasian population is around 25–40% [67]. According to
a recently published case report, patients who are homozygous to haplotype (C.2677G>T; TT and
C.3435C>T; TT) may have higher plasma levels, Cmax, half-life, and increased risk of bleeding
complications [67]. Pharmacogenomic screening of this haplotype mutation may be warranted
particularly in patients with risk factors such as renal impairment and CYP3A5 inhibitors [67].
Another ABCB1 genetic variant (1236 C>T) was also studied, and the combined ABCB1 haplotype
(1236-2677-3435) did not have any significant effect on pharmacokinetic metabolism of rivaroxaban [55].
A summary of pharmacogenetic studies performed with rivaroxaban is listed in Table 2.
Table 2. Common genetic variants associated with pharmacodynamics and pharmacokinetics
of rivaroxaban.
Gene Exon SNP DNAPolymorphism
Changes in Peak
Plasma Levels
Study
Population Reference Year
ABCB1 21 rs2032582 C.2677G>T Increased Casereport [67] 2016
ABCB1 2126
rs2032582
rs1045642
Combined
haplotype
(2677–3435)
C.2677G>T
C.3435C>T
Non-significant
increase
Healthy
volunteers [55] 2016
ABCB1 26 rs1045642 C.3435C>T Casereport [67] 2016
ABCB1 —
rs1128503
Combined
haplotype
(1236–2677–3455)
C.1236C>T No Change Healthyvolunteers [55] 2016
Peak levels of Rivaroxaban associated with gene loci and their single nucleotide polymorphisms in recently
conducted clinical studies.
3.3. CYP3A
Sychev et al. reported a significant correlation between CYP3A activity and rivaroxaban peak and
trough levels in patients with deep vein thrombosis [70]. However, no significant correlation between
CYP3A activity and treatment parameters in deep vein thrombosis patients treated with rivaroxaban
were found [70]. A summary of genetic variants analyzed for rivaroxaban is provided in Table 2.
4. Apixaban
Apixaban is widely used in prevention of stroke in non-valvular atrial fibrillation and treatment
of deep vein thrombosis and pulmonary embolism [71].
Moreover, apixaban is considered a cost effective therapeutic option in comparison to warfarin
across different economic evaluations, such as willingness to pay thresholds, discount rates, medical
costs, and healthcare systems for stroke prevention in non-valvular atrial fibrillation [72]. It has
also been shown to be equally efficacious as compared to enoxaparin and warfarin in prevention of
recurrent venous thromboembolism in adults with acute VTE [73,74]. It is used for treatment of deep
vein thrombosis and pulmonary embolism, as well as prevention of venous thromboembolism after
orthopedic surgery [73]. Its main mechanism of action is through reversible inhibition of factor Xa.
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It specifically binds and inhibits both free and bound factor Xa which ultimately results in reduction in
the levels of thrombin formation [75].
Some of the important pharmacokinetic features of apixaban include 50% bioavailability,
peak levels reached within 1–2 h, 87% bound to plasma proteins, 21 L volume of distribution,
a half-life of 12 h, hepatic CYP450 metabolism, and 25% renal excretion [73,75,76]. Apixaban
is mainly metabolized by CYP3A4 with minor contributions from CYP1A2, CYP2C8, CYP2C9,
CYP2C19 and CYP2J2 isoenzymes [54]. Some of the major metabolic pathways of apixaban include
o-demethylation, hydroxylation, and sulfation, with o-demethyl apixaban sulphate being the major
metabolite (Supplemental Figure S3) [77]. The principal modes of elimination of apixaban include
fecal (56%) and renal pathways (24.5%) [77]. In view of multiple modes of metabolism and elimination,
it appears to be safe to use in patients with renal or hepatic impairment [77].
Major bleeding episodes with apixaban may be treated with prothrombin complex concentrates
(PCCa) and andexanet alpha [54,78].
4.1. Pharmacogenomics
Apixaban is a substrate for p-gp and CYP450 enzymes (3A4) and thus caution should be
exercised during concomitant administration of strong inducers and inhibitors of both metabolic
pathways [50,75]. Strong inducers of CYP3A4 and p-gp such as rifampicin/rifampin, carbamazepine,
phenytoin, and phenobarbital can reduce the plasma levels of apixaban and result in a decrease
in its therapeutic effect. Conversely, strong inhibitors of CYP3A4 and p-gp such as ketoconazole,
itraconazole, ritonavir, and clarithromycin can lead to supra-therapeutic levels of apixaban and
excessive bleeding tendencies [50,75]. Moderate CYP3A4 and p-gp inhibitors such as erythromycin
and clarithromycin can be co-administered with apixaban as their clinical impact is not clearly defined.
4.2. SULT1
A potentially important pharmacogenomic metabolic pathway is through sulfotransferases
(SULTs) SULT1A1 and SULT1A2, which are responsible for sulfation of o-demethyl-apixaban to
o-demethyl-apixaban sulphate [31,79,80]. SULT1A1 is more potent than SULT1A2 in sulfation of
o-demethyl-apixaban [79]. O-demethyl-apixaban is the most prominent metabolite and represents 25%
of estimated active apixaban [77].
Is it important to know that o-demethyl-apixaban sulphate does not possess any inhibitory activity
against factor Xa that can contribute to anticoagulant efficacy of apixaban [79]. Three important allelic
variants, SULT1A1*1 (wild type), SULT1A1*2, and SULT1A1*3 have been described [80]. Vmax of all
the three allelic variants of SULT1A (SULT1A*1 > SULT1A*3 > SULT1A*2) varies and it accounts for
differences in sulfation of active apixaban [81]. SULT1A*3 has moderate potential to affect anticoagulant
effect of apixaban, whereas SULT1A*2 has very low potential effect on metabolism of apixaban
(Table 3) [81].
Table 3. Allelic variants of sulfomethyl transferase SULF1A1 that affect the pharmacokinetic metabolism
of apixaban.
SULT1A AllelicVariants Substitution Whites Blacks Chinese Reference
SULT1A1*1 Wild type 65.6% 47.7% 91.4% [80–83]
SULT1A1*2 G to A change atnucleotide 638 33.2% 29.4% 8% [80–83]
SULT1A1*3 A to G change atnucleotide 667 1.2% 22.9% 0.6% [80–83]
These different alloenzymes have different enzymatic efficacies and may lead to different
metabolite concentrations and variations in anticoagulant efficacy of apixaban [81,82]. The impact
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of common genetic variants of SULT1A1 on apixaban metabolism in patients however has not been
formally tested as of yet.
4.3. ABCB1
ABCB1 rs4148738 is significantly associated with variability of peak levels of apixaban as compared
to trough levels [83]. Particularly, AA genotype of rs4148738 had higher peak levels of apixaban as
compared to carriers of variant G allele [83]. Specifically, peak levels of apixaban in carriers of ABCB1
rs4148738 G variant are decreased by 26% in heterozygytes and 32% in homozygotes [83]. The authors
concluded that p-glycoprotein may account for some of the genetic variation in peak plasma levels
of apixaban [83]. A study by Valarevich et al. showed no significant association of ABCB1 SNPs
(rs1045642 and rs4148738), as well as CYP3A5*3 (rs776746) with pharmacokinetics of apixaban in
patients with atrial fibrillation and stroke [84]. A summary of pharmacogenetic studies performed
with apixaban is provided in Table 4.
Table 4. Common genetic variants associated with variation in pharmacokinetics and pharmacodynamics
of apixaban.
Apixaban
Levels SNP Genotype Locus Function Change
Clinical
Outcome Ref. Year
Peak levels rs4148738 G>A ABCB1 Intron Increase Nottested [83] 2016
Peak levels
and AUC rs1045642 CC, CT, TT ABCB1 Intron
No significant
difference
Not
tested [84] 2018
Peak levels
and AUC rs4148738 CC, CT, TT ABCB1 Intron
No significant
difference
Not
tested [84] 2018
Peak levels
and AUC rs776746 CC, CG, GG CYP3A5 Intron
No significant
difference
Not
tested [84] 2018
Peak and trough levels of Apixaban and clinical outcomes associated with gene loci and single nucleotide
polymorphisms in clinical studies.
5. Edoxaban
Edoxaban is a direct oral anticoagulant approved for prevention of stroke and systemic embolism
in patients with non-valvular atrial fibrillation [2]. It has also shown efficacy in prevention of recurrent
venous thromboembolism in patients undergoing total knee replacement surgery as compared to
warfarin and enoxaparin [2,85]. Its mechanism of action is through competitive inhibition of factor
Xa in a highly selective manner [3,86,87]. Inhibition of factor Xa activity is the main mechanism of
action that leads to reduction in thrombin generation and thrombus formation, which also indirectly
results in decrease in platelet activation [3,87]. It has been shown to prolong prothrombin time (PT),
and activated partial thromboplastin time (aPTT), and to decrease thrombin generation in thrombin
generation (TG) assay [3]. In animal models of venous stasis, edoxaban has been shown to inhibit
factor Xa activity and thrombus formation [3,88]. In animal models of arterial thrombosis, edoxaban in
combination with aspirin and clopidogrel has afforded additive antithrombotic effects with excessive
bleeding tendencies only in combination with clopidogrel [3,89,90].
Some of the important pharmacokinetic parameters with edoxaban include rapid absorption
through upper gastrointestinal tract (1–3 h), 62% bioavailability, peak plasma concentration reached
within 1–2 h, 107 L volume of distribution, 40–59% plasma protein binding, half-life 10–14 h,
total clearance 22 L/h with elimination by kidney, and hepatic metabolism [3,86,87,91]. Systemic
exposure levels of edoxaban do not seem to be affected by food or hepatic impairment, but dosage
adjustment is needed for renal impairment [87,91,92].
Edoxaban undergoes extensive metabolism through CES1, CYP3A4, and glucuronidation [91].
Edoxaban can be metabolized into various metabolites such as M1 (Hydrolysis), M3 (conjugation),
M4 (CES1), M5 (CYP3A4), M6 (CYP3A4), and M7 (CYP3A4) (Supplemental Figure S4) [91].
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All the metabolites, including the most abundant metabolite M4, do not significantly contribute to
anticoagulant activity [91]. Metabolite M4 is a substrate for organic anion transporter 1B1 (OATP1B1).
Changes in the levels of OATP1B1 affect edoxaban and M4 plasma concentration [93]. Bleeding caused
by supra-therapeutic levels of edoxaban can be treated with factor VIIa concentrates, prothrombin
complex concentrates, anti-inhibitor coagulation complex, andexanet alpha, and synthetic small
molecule (PER977) [3,54].
5.1. Pharmacogenomics
Endoxaban is a substrate of p-gp and CYP3A4. Major drug interactions of edoxaban can be
observed with strong and moderate inducers or inhibitors of both p-gp and CYP3A4 [3,26,86,87,91].
Co-administration with inhibitors of p-gp and CYP3A4 (ketoconazole, quinidine, verapamil,
erythromycin, cyclosporine, and amiodarone) results in increase in peak levels and total exposure
of edoxaban [3,86,87,91]. Administration of rifampicin/rifampin (strong p-gp inducer) along with
edoxaban results in decrease in total exposure and peak levels [91]. Drugs such as aspirin, naproxen,
digoxin, atorvastatin, and esomeprazole did not alter the peak levels, Cmax, AUC, and total exposure
levels of edoxaban [3,91].
5.2. ABCB1
In a study recently conducted by Vandell et al., ABCB1* SNP (rs1045642; C3435T) and SLCO1B1
SNP (rs4149056; T521C) were found to have no significant effect on the pharmacokinetics of edoxaban,
although the same study showed a significant increase in plasma levels of edoxaban and slight
elevation of M4 metabolite (SLCOB1B1 C-allele carriers) with p-gp and OATP1 inhibitors [93].
5.3. CYP2C9 and VKORC1
In a recent randomized double blinded study comparing edoxaban with warfarin in the treatment
of venous thromboembolism (Hokusai VTE), CYP2C9 SNPs (rs1799853 and rs1057910) and VKORC1
SNP (rs9923231) did not have any significant impact on the risk of major bleeding episodes or
clinical response in subjects randomized to edoxaban [94]. In the randomized double blinded
study comparing edoxaban with warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI48),
there was a trend towards the consistent long-term safety benefit of edoxaban over warfarin across
genotypes [95]. Mega et al. also found that patients with CYP2C9 (rs1799853 and rs1057910) and
VKORC1 (rs9923231) genotypes derived greater safety benefit from edoxaban compared with warfarin
by identifying patients who are more likely to experience early bleeding with warfarin [95]. A summary
of pharmacogenetic studies performed with edoxaban is provided in Table 5.
Table 5. Pharmacogenomic studies of edoxaban.
Clinical Trial Gene SNP DNAPolymorphism Study Population
Effect on Edoxaban
Levels
Clinical
Outcomes Ref. Year
Integrated analysis of 14
phase I studies ABCB1 rs1045642 C3435T Healthy population No effect Not tested [93] 2018
Integrated analysis of 14
phase I studies SLCO1B1 rs4149056 T521C Healthy population
Slight increase in
M4 metabolite Not tested [93] 2018
Randomized Double blind CYP2C9 rs1799853 — VenousThromboembolism Not tested No effect [94] 2017
Randomized Double blind CYP2C9 rs1057910 — VenousThromboembolism Not tested No effect [94] 2017
Randomized Double blind VKORC1 rs9923231 — VenousThromboembolism Not tested- No effect [94] 2017
Randomized Double blind CYP2C9 rs1799853 — Atrial Fibrillation Not tested No effect [95] 2015
Randomized Double blind CYP2C9 rs1057910 — Atrial Fibrillation Not tested No effect [95] 2015
Randomized Double blind VKORC1 rs9923231 — Atrial Fibrillation Not tested No effect [95] 2015
Pharmacokinetics and clinical outcomes associated with gene loci and single nucleotide polymorphisms tested in
clinical studies of Edoxaban.
J. Pers. Med. 2019, 9, 7 11 of 18
6. Conclusions and Future Perspective
Despite broad therapeutic windows of novel oral anticoagulants, there has been recognition
that both pharmacogenomics as well as relevant drug-drug interactions can lead to variability in
plasma drug levels [53]. In the case of dabigatran, CES1 and ABCB1 genes and their SNPs have
been associated with variability in plasma drug levels of dabigatran, whereas ABCB1 and CYP3A4
is implicated in altering plasma drug levels of rivaroxaban. SULTA1A, a relatively novel candidate
gene identified as important in the metabolism of apixaban, as well as known variants in ABCB1
gene have been implicated in altering plasma drug levels of apixaban. While associations have been
described between alterations in drug levels of most DOAC and important pharmacogenetic pathways,
there has been fewer data showing linkage of variants with either bleeding or thromboembolic events.
This review summarizes the clinical studies conducted for each drug. The lack of solid clinical
outcomes data from large enough clinical trial cohorts limits the scope of recommendations drawn
from the pharmacogenetic and pharmacokinetic studies.
For warfarin, the Clinical Pharmacogenetics Implementation Consortium (CPIC) was created for
designing genotype-based dosing algorithms for appropriate dosage adjustments in patient specific
clinical scenarios [24,25]. Before similar genotype-based dosing algorithms for DOACs could be
generated, further prospective clinical studies would be needed.
Genetic variants of genes including ABCB1 and CES1 might be responsible for some of
inter-individual variability of DOACs. We have summarized genetic variants reported to be associated
with altered drug levels of DOACs in Figure 1 and frequency in populations in Table 6. Sometimes these
genetic variants might be in linkage disequilibrium with other unknown genetic variants, which needs
to be taken into consideration for interpreting dug variability and anticoagulant efficacy of DOACs [30].
Apart from these variants, other factors such as rare mutations, epigenetic mechanisms,
DNA methylation, and environmental factors might also contribute to inter-individual variation
of DOACs [26]. Genome wide association studies are warranted for identifying additional genetic
variants that are involved in metabolism and transport of DOACs and their impact on anticoagulant
efficacy and adverse effects [26]. Since there are around 2000 genetic polymorphisms in the CES1
gene, a focused CES1 pharmacogenetic study may potentially uncover genomic variants that might
influence the metabolism and clinical outcome of dabigatran usage [51]. Although ABCB1 gene variants
did not significantly influence the inter-individual variability of rivaroxaban plasma concentrations
in some studies, future research is warranted to understand its role in combination with CYP3A4
genetic polymorphisms [30,55,96]. ABCG2 (BRCP efflux transporter), CYP3A4/5, and CYP2J2 genetic
polymorphisms should also be studied to understand their impact on inter-individual variability of
rivaroxaban pharmacokinetics [54,67,96]. Genetic variants of sulfotransferase (SULT1A1), which is
involved in metabolism of apixaban, needs additional clinical studies to ascertain its effect on clinical
efficacy and side effects [79].
Direct oral anticoagulants demonstrate a wide therapeutic index and, while safer than Vitamin
K antagonists, their use is associated with both adverse bleeding events as well as sub-therapeutic
inhibition of coagulation.
In conclusion, pharmacogenomics of novel direct oral anticoagulants is a relatively new field of
research. Important genetic variants affecting DOAC pharmacokinetics described in this review need
further consideration. Further clinical studies are required to better understand the impact of variations
in DOAC drug levels related to pharmacogenomics on actual clinical outcomes, both in terms of risk
of bleeding as well as risk of diminished clinical efficacy (lack of protection from thrombotic events).
Understanding the importance of genetic variants in metabolism and transport of novel DOACs might
lead to effective personalized therapy and better clinical outcomes.
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Table 6. Genotype distributions of common variants of ABCB1 and CES1.
Gene SNP Genotype Ethnic Group N % Minor Allele MAF% p-Value Reference
CES1 rs2244613 CC Caucasian 2 C 22.3 0.230 Dimatteo et al. [30]
CA 37
AA 53
ABCB1 rs1045642 CC Russian 15 T 50.8 0.49 Sychev et al. [52]
CT 29
TT 16
ABCB1 rs4148738 GG Caucasian 27 A 47.3 0.678 Dimatteo et al. [30]
AG 43
AA 22
ABCB1 rs8192935 CC Caucasian 43 T 31.5 0.956 Dimatteo et al. [30]
CT 40
TT 9
MAF: Mean allelic frequency.
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7. Executive Summary
7.1. Direct Oral Anticoagulants
- To offset e significant challe ges po ed by vitamin K antagonists (warfarin) such as narrow
therapeutic index, drug interactio s, and frequent coagulation monitoring newer direct oral
anticoagulants (DOACs) were introduced.
- Four DOACs that are currently in clinical use include dabigatran, rivaroxaban, apixaban,
and edoxaban.
- DOACs act on specific coagulation factors inhibiting thrombin generation.
- Currently approved indications of DOACs include prophylaxis against thromboembolism in
non-valvular atrial fibrillation, treatment and prevention of deep vein thrombosis and pulmonary
embolism, and secondary prevention in chronic coronary artery and peripheral vascular disease.
- DOACs are cost effective and improve quality of life as compared to warfarin in approved
clinical conditions.
7.2. Dabigatran
- Dabigatran acts through reversible competitive inhibition of thrombin.
- It is administered as prodrug that is converted into active form dabigatran etelixilate by esterases.
- Principal drug interactions are mediated by p-glycoprotein.
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- CES1 and ABCB1 gene loci and their SNPs are implicated in altering plasma peak and trough
levels of dabigatran.
7.3. Rivaroxaban
- Rivaroxaban acts through inhibition of factor Xa.
- Principal drug interactions are mediated by CYP3A4 and p-glycoprotein.
- ABCB1 and CYP3A4 gene loci and their SNPs are implicated in altering plasma drug levels
of rivaroxaban.
7.4. Apixaban
- Apixaban acts through reversible inhibition of factor Xa.
- Principal drug interactions are mediated by CYP3A4 and p-glycoprotein.
- ABCB1 gene locus and its SNPs are implicated in altering plasma drug levels of apixaban.
- Sulfotransferases polymorphisms may potentially contribute to variability of
apixaban metabolism.
7.5. Edoxaban
- Edoxaban acts through inhibition of factor Xa.
- Principal drug interactions are mediated by CYP3A4 and p-glycoprotein.
- Clinical trials failed to show significant association between ABCB1, CYP2C9, and VKORC1 and
plasma drug levels of edoxaban.
8. Conclusions
- Drug-gene interactions of DOACs are mainly mediated by genes CES1, ABCB1, and CYP3A4 and
their respective SNPs.
- Drug-drug interactions of DOACs are mainly mediated by CYP3A4 and p-glycoprotein. Further
research including larger randomized clinical trials should be conducted to uncover other genetic
variants and understand their impact on plasma drug levels and clinical efficacy of DOACs.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2075-4426/9/1/7/s1.
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